Innovative Cancer Detection Micronoma specializes in microbiome-driven liquid biopsy technology for early cancer detection, presenting a unique opportunity to integrate advanced diagnostics into clinical practices and expand into oncology-focused healthcare markets.

Strategic Collaborations Partnership with New York University and ongoing collaborations with the National Cancer Institute highlight opportunities to co-develop and commercialize microbial biomarker-based tests, potentially attracting research and healthcare institutions as clients.

Regulatory Milestones Receiving FDA Breakthrough Device Designation for its OncobiotaLUNG assay demonstrates progression toward regulatory approval, creating sales opportunities in hospital systems and diagnostic labs seeking innovative approved solutions.

Funding and Growth With $6.5M in funding and a focus on early-stage cancer detection, Micronoma is positioned for rapid product development and commercialization, offering opportunities to engage investors, clinical partners, and early adopters in the biotech ecosystem.

Market Positioning As a pioneering biotech firm in microbiome-based diagnostics with a dedicated clinical and research team, Micronoma presents a compelling partnership opportunity for companies seeking to expand their molecular diagnostics portfolio or enhance cancer detection capabilities.